WO2020001644A1 - 甘露糖醛二酸的组合物在治疗糖尿病中的应用 - Google Patents

甘露糖醛二酸的组合物在治疗糖尿病中的应用 Download PDF

Info

Publication number
WO2020001644A1
WO2020001644A1 PCT/CN2019/093822 CN2019093822W WO2020001644A1 WO 2020001644 A1 WO2020001644 A1 WO 2020001644A1 CN 2019093822 W CN2019093822 W CN 2019093822W WO 2020001644 A1 WO2020001644 A1 WO 2020001644A1
Authority
WO
WIPO (PCT)
Prior art keywords
mannuronic acid
composition
total weight
use according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/093822
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
耿美玉
辛现良
张真庆
丁健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Priority to AU2019296855A priority Critical patent/AU2019296855A1/en
Priority to KR1020217001851A priority patent/KR20210038875A/ko
Priority to JP2020572806A priority patent/JP2021528459A/ja
Priority to US17/256,889 priority patent/US11406652B2/en
Priority to EP19824488.1A priority patent/EP3815690A4/en
Publication of WO2020001644A1 publication Critical patent/WO2020001644A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to the application of the best composition of mannanuronic acid obtained through biological activity screening method in the treatment of diabetes.
  • Diabetes is a frequently-occurring and common disease that seriously endangers human health. Especially with the increasing number of elderly people in the world, its incidence has been increasing year by year. Therefore, the prevention and treatment of diabetes is becoming more and more important.
  • the commonly used drugs for the prevention and treatment of diabetes in clinical practice mainly include insulin and oral hypoglycemic drugs, which often have disadvantages such as inconvenience in use and large toxic and side effects, especially the lack of suitable effective drugs for type II diabetes.
  • Mannuronic acid has been widely valued for its potential medicinal value.
  • Mannuronic acid is usually prepared from alginic acid through multiple steps.
  • M and G sections can be separated from the raw alginic acid.
  • the general method can be simply described as: after the initial degradation of alginic acid, a mixed polysaccharide of polymannuronic acid and polyguluronic acid can be obtained, and after the mixed polysaccharide is precipitated by the acid method, the polyguluraldehyde can be removed therefrom Acid and further purification to obtain a homopolymannuronic acid (hereinafter also referred to as "M-stage intermediate") having a purity of 90% or more.
  • M-stage intermediate homopolymannuronic acid
  • the general method for preparing oligomannuronic acid is as follows: the M-stage intermediate obtained above is heated under acidic conditions and further acidolyzed to obtain small fragments of mannuronic acid polymers in the desired molecular weight range.
  • the reducing terminal can be oxidized to a ring-opened sugar diacid.
  • Patent Documents 1 and 2 are hereinafter collectively referred to as prior patents, which are all incorporated herein by reference.
  • reaction process of the mannuronic acid disclosed in the prior patent can be represented by the following reaction equation (II), that is, the oxidizing group at the C1-position of the mannuronic acid at the reducing end of the oligomannuronic polysaccharide is oxidized to a carboxyl group.
  • a common oxidant is a basic copper sulfate solution, that is, a film reagent.
  • This oxidation method was adopted in a prior patent. Specifically, under alkaline conditions, the reaction substrate is polymannuronic acid, namely The above M-stage intermediate is added to the copper sulfate solution and reacted in a boiling water bath for 15 minutes to 2 hours. This method uses Cu 2+ ions as oxidant to oxidize aldehyde groups. Brick red cuprous oxide precipitates during the reaction. This reaction is often used to identify reducing sugars.
  • mannan oligosaccharide diacid has anti-Alzheimer's disease (AD) and anti-diabetic effects.
  • AD Alzheimer's disease
  • type 2 diabetes The pathogenesis of Alzheimer's disease and type 2 diabetes is closely related to amyloid ( ⁇ -amyloid and amylin).
  • Amyloid aggregates to produce protein oligomers, which further aggregate to form fibers.
  • These protein aggregates are cytotoxic, induce oxidative reactions in cells to damage mitochondria, and trigger a cascade of diabetic responses, causing a large number of neurons and ⁇ -cell damage, eventually leading to Alzheimer's disease and type II diabetes.
  • Mannan oligosaccharic acid targets amyloid and antagonizes the cascade response induced by it, thereby preventing and treating Alzheimer's disease and type 2 diabetes.
  • the invention relates to the use of a mannuronic acid oligosaccharide composition in the treatment of diabetes.
  • the invention also relates to a method for treating diabetes, which comprises administering to a patient in need of treatment a therapeutically effective amount of the mannuronic acid oligosaccharide composition according to the invention.
  • the mannuronic acid oligosaccharide composition used in the present invention has a specific composition and comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1-9
  • m is selected from 0, 1 or 2
  • m ' is selected from 0 or 1
  • the total weight of n 1-5 of the mannuronic acid accounts for more than 60% of the total weight of the composition
  • Figure 1 is the mass spectrum of disaccharide, trisaccharide and tetrasaccharide in product A.
  • FIG. 2 is a mass spectrum of pentasaccharide, hexasaccharide, and heptose in product A.
  • FIG. 2 is a mass spectrum of pentasaccharide, hexasaccharide, and heptose in product A.
  • Figure 3 is a mass spectrum of octaose, nonasaccharide, and decasaccharide in product A.
  • Fig. 4 shows the protective effect of mannan oligosaccharide diacid of each single degree of polymerization on amylin-induced islet ⁇ cells, and the numerical value on the abscissa indicates the degree of polymerization of each oligosaccharide.
  • Figure 5 shows the effect of oligosaccharide composition and hexasaccharide on postprandial blood glucose in diabetic mice; the samples corresponding to the numbers on the abscissa in the figure are: i: control group; ii: model group; iii: product A; iv: product B; v: Product C; vi: Product D; vii: Hexose.
  • the invention relates to the use of a mannuronic acid oligosaccharide composition in the treatment of diabetes.
  • the invention also relates to a method for treating diabetes, which comprises administering to a patient in need of treatment a therapeutically effective amount of the mannuronic acid oligosaccharide composition according to the invention.
  • the mannuronic acid oligosaccharide composition used in the present invention has a specific composition and comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1-9
  • m is selected from 0, 1 or 2
  • m ' is selected from 0 or 1
  • the total weight of n 1-5 of the mannuronic acid accounts for more than 60% of the total weight of the composition
  • the mannuronic acid oligosaccharide composition according to the present invention is a mixture of mannuronic acid with different polymerization degrees, and its main component is a mannuronic acid oligosaccharide having a polymerization degree of 2 to 10. It is known that among mannuronic acids, the most active sugars are 4-10 sugars, especially 6 sugars. However, the inventors have now discovered that adding a certain proportion of the less active 2-3 sugars to the 4-10 sugars with the highest activity, the biological activity does not decrease or even increases at the same quality of the administered dose.
  • the ratio is between 1.0 and 3.5, preferably between 1.0 and 3.0.
  • the weight percent content of each degree of polymerization of the mannuronic acid oligosaccharide in the mannuronic acid oligosaccharide composition of the present invention in the composition is: 5-25% of disaccharide, three 15-30% of sugar, 15-28% of tetrasaccharide, 5-25% of pentasaccharide, 2-20% of hexasaccharide, 2-20% of heptasaccharide, 2-20% of octose, 2-20% of nonaperose, and ten sugar 2-20%.
  • the weight percentage content of oligosaccharides in the composition is: 5-25% disaccharides, 15-30% trisaccharides, 15-28% tetrasaccharides, 10-20% pentasaccharides, 5-15% hexasaccharides, Heptasaccharide is 3-10%, octose is 2-5%, nonaose is 1-5%, and decaose is 1-5%. More preferably, the weight percentage of oligosaccharides in the composition is: 10-20% disaccharides, 18-30% trisaccharides, 15-28% tetrasaccharides, 15-20% pentasaccharides, and 5-10% hexasaccharides. , Heptasaccharide 3-5%, octaose 2-5%, nonaose 1-3%, and ten sugar 1-3%.
  • the pharmaceutically acceptable salt is a sodium salt or a potassium salt.
  • each individual oligosaccharide is compounded according to a certain ratio, a highly active oligosaccharide composition can be obtained, the activity of which is higher than the most active hexasaccharide; especially it contains a certain ratio
  • the composition of disaccharide and trisaccharide has higher activity than the composition of disaccharide and trisaccharide.
  • the ratio of each oligosaccharide in the high-activity oligosaccharide composition needs to be combined according to the following proportional relationship:
  • the medicament for treating diabetes comprises a mannuronic acid oligosaccharide composition comprising a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof, and one or more medicaments Acceptable carrier.
  • the medicament according to the invention may be tablets, hard capsules, soft capsules, enteric capsules, microcapsules, granules, syrups, injections, granules, emulsions, suspensions, solutions and for oral or parenteral administration In the form of a slow-release preparation.
  • the pharmaceutically acceptable carrier in the present invention refers to a pharmaceutically acceptable carrier well known to those skilled in the art.
  • the pharmaceutically acceptable carrier in the present invention includes, but is not limited to, fillers, wetting agents, adhesives, and disintegrating agents. , Lubricants, adhesives, glidants, taste-masking agents, surfactants, preservatives, etc.
  • Fillers include, but are not limited to, lactose, microcrystalline cellulose, starch, powdered sugar, dextrin, mannitol, calcium sulfate, and the like.
  • Wetting agents and binders include, but are not limited to, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelatin, sucrose, polyvinylpyrrolidone, and the like.
  • Disintegrating agents include, but are not limited to, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and the like.
  • Lubricants include, but are not limited to, magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycol, magnesium lauryl sulfate, and the like.
  • Binders include, but are not limited to, gum arabic, alginic acid, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, glucose binding agents, dextrin, dextrose, ethyl cellulose, gelatin, liquid glucose, guar Gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, magnesium aluminum silicate, maltodextrin, methyl cellulose, polymethacrylate, polyvinylpyrrolidone, pregelatinized starch , Sodium alginate, sorbitol, starch, syrup and tragacanth.
  • Glidants include, but are not limited to, colloidal silica, powdered cellulose, magnesium trisilicate, silica, and talc.
  • Taste-masking agents include, but are not limited to, aspartame, stevioside, fructose, glucose, syrup, honey, xylitol, mannitol, lactose, sorbitol, maltitol, glycyrrhizin.
  • Surfactants include, but are not limited to, Tween-80, Poloxamer.
  • Preservatives include, but are not limited to, paraben, sodium benzoate, potassium sorbate, and the like.
  • treatment generally refers to obtaining the desired pharmacological and / or physiological effect.
  • the effect may be preventive based on the complete or partial prevention of the disease or its symptoms; and / or based on the partial or complete stabilization or cure of the disease and / or side effects due to the disease, which may be therapeutic.
  • treatment covers any treatment of a patient's disease, including: (a) preventing a disease or symptom that occurs in a patient who is susceptible to a disease or symptom but has not yet been diagnosed; (b) suppressing the symptoms of the disease, That is, preventing its development; or (c) alleviating the symptoms of the disease, that is, causing the disease or the symptoms to deteriorate.
  • the mannuronic acid oligosaccharide composition for treating diabetes comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1-9
  • m is selected from 0, 1 or 2
  • m ' is selected from 0 or 1
  • the method for preparing the mannuronic acid oligosaccharide composition for treating diabetes includes the following steps:
  • the M-stage intermediate of the raw materials used in the present invention can be prepared by methods known in the art. For example, the methods disclosed in Chinese Patent Application No.98806637.8 and CN02823707.2.
  • the general method can be simply described as: after the initial degradation of alginic acid, a mixed polysaccharide of polymannuronic acid and polyguluronic acid can be obtained, and after the mixed polysaccharide is precipitated by the acid method, the polyguluraldehyde can be removed Acid, further purification can obtain a homopolymannuronic acid with a purity of more than 90%, that is, an M-stage intermediate.
  • the M-stage intermediate is dissolved in an appropriate amount of water at room temperature or under heating conditions, stirred, and ozone is continuously introduced, and the reaction starts.
  • the reaction pH can be adjusted to between 3 and 13, preferably 4 to 10, and more preferably 6 to 8 by the addition of dilute hydrochloric acid or dilute NaOH solution.
  • the temperature is preferably 0-70 ° C, and more preferably 10-45 ° C.
  • the reaction product obtained above was prepared into a solution having a concentration of about 10%, and was separated by a molecular cut-off membrane to remove degradation products below monosaccharides, and the impermeable liquid was collected.
  • the molecular retention membrane MWCO used has a specification of 1000 Da to 3000 Da, preferably 2000 Da.
  • the collected solution was concentrated on a rotary evaporator and vacuum dried to obtain an oligomannuronic acid mixture. After analysis, it was found that these products are all disaccharide-decasaccharide oligosaccharides whose composition is in a certain ratio range. Examples 1-3 are examples of the method steps.
  • the oligosaccharide mixture obtained in step (1) is dissolved, formulated to a concentration of about 10%, separated by a P6 gel chromatography column, and detected by UV, and each effluent component is collected, and components with the same degree of polymerization are combined.
  • Nine components of 2-10 sugars were collected, desalted by G10 gel column chromatography, concentrated on a rotary evaporator, and dried under vacuum.
  • a specific purification preparation process can be seen in Example 4.
  • the nine oligosaccharides with a single degree of polymerization were evaluated for their pharmacological activity using anti-diabetic animal models, and it was found that the activity of hexasaccharide was the best.
  • Human pancreatic islet ⁇ -cell NIT strain was cultured in DMEM medium containing 10% FBS, and inoculated in a 96-well plate at 1 ⁇ 104 cells / well. After the cells were fused, a single degree of polymerization of 100 ⁇ g / m1 was added for 24 hours. Normal control group and model group were added with the same amount of normal saline; model group and single polymerization degree oligosaccharide group were added with aging amylin (amylin, also known as islet amyloid peptide, referred to as IAPP) at a final concentration of 30 ⁇ M. Normal control group The same amount of physiological saline was added, and after 48 hours of incubation, cell survival was measured by the MTT method.
  • mice Male NIH mice were randomly selected into a normal control group, a model group, and an administration group, with 10 mice in each group. On the day of the test, all animals except the normal group were injected with streptozotocin 150 mg / kg intraperitoneally. The corresponding drugs were continuously administered for 10 days. On the 11th day, the eyeballs were removed to take blood, and the blood glucose concentration was measured.
  • Step 1) Preparation of mannuronic acid oligosaccharide mixture
  • the method of preparing the M-stage intermediate as disclosed in the previous patent is briefly described as follows: 5Kg of sodium alginate is prepared into a solution of about 10%, and diluted hydrochloric acid is added to adjust the pH to about 3.0, and the temperature is raised to 80 ° C, stirred, and reacted. 10hr, stop heating, cool to room temperature, add NaOH to adjust pH to 9.0, add dilute hydrochloric acid to adjust pH to 2.85, centrifuge at 5000rpm for 10min, collect supernatant, add HCl to adjust pH to 1.0, centrifuge, collect precipitate, rotate The evaporator was concentrated and dried under vacuum to obtain 1500 g of M-stage intermediate.
  • Step 2) Proportion and structure analysis of oligosaccharides with various polymerization degrees in mannuronic acid product A
  • disaccharides-decasaccharides are represented by dp2-dp10, respectively, dp2 is 19%, dp3 is 25%, dp4 is 22%, dp5 is 13%, dp6 is 9%, dp7 is 6%, and dp8 is 3 %, Dp9 is 2%, and dp10 is 1%.
  • Step 3) LC-MS analysis of the structure of oligosaccharides with various degrees of polymerization in Mannuronic acid product A
  • Mass spectrometry conditions Agilent 6540 QTOF; ion source: ESI collision voltage 120V; negative ion mode.
  • the acquisition signal (m / z) width is 100-1000.
  • Example 1 100 g of the M-stage intermediate in Example 1 was weighed, dissolved in distilled water, and prepared into a volume of 0.8 L. The solution was adjusted to pH 4.0 with NaOH and reacted at room temperature at 25 ° C. The gas flow at the outlet of the oxygen cylinder and the power of the ozone generator were adjusted so that the ozone mass concentration flow reached 1 g / hr and passed into the reaction solution. After 10 hours of reaction, stop introducing ozone, add appropriate amount of water to adjust the solution concentration to about 15%, and filter with an ultrafiltration membrane with a molecular weight cut off of 1000 Da. Collect the impervious liquid, concentrate on a rotary evaporator, and dry in vacuo to obtain 80 g of mannaldehyde Acid Product B.
  • GE Superdex peptide
  • MALS multi-angle laser scattering
  • dp2-dp10 Disaccharides-decasaccharides are represented by dp2-dp10, respectively, dp2 is 20%, dp3 is 25%, dp4 is 19%, dp5 is 12%, dp6 is 9%, dp7 is 5%, and dp8 is 5 %, Dp9 is 3%, and dp10 is 2%.
  • Example 1 100 g of the M-stage intermediate in Example 1 was weighed, dissolved in distilled water, and then a 1.5 L volume solution was prepared. The pH was adjusted to 9.0 with NaOH, and the reaction was performed at 45 ° C in a water bath. The gas flow at the outlet of the oxygen cylinder and the power of the ozone generator were adjusted so that the ozone mass concentration flow reached 3 g / hr and passed into the reaction solution. After reacting for 2 hours, stop introducing ozone, add an appropriate amount of water to adjust the solution concentration to about 5%, and filter through an ultrafiltration membrane with a molecular weight cut-off of 3000 Da. Collect the impervious liquid, concentrate on a rotary evaporator, and dry in vacuo to obtain 60 g of mannaldehyde. Acid Product C.
  • GE Superdexpeptide
  • MALS multi-angle laser scattering
  • dp2-dp10 disaccharides-decasaccharides are represented by dp2-dp10, respectively, dp2 is 8%, dp3 is 20%, dp4 is 28%, dp5 is 19%, dp6 is 13%, dp7 is 6%, and dp8 is 3 %, Dp9 is 2%, and dp10 is 1%.
  • Step 1) The preparation of mannuronic acid oligosaccharide with a single degree of polymerization is as follows:
  • Sample preparation Take 300g from the mannuronic acid product A prepared in Example 1, dissolve it with water, configure it into a 1000mL concentrated solution, and place it in a 4 ° C refrigerator for later use. After each use, 50 mL was taken out and diluted with water, and then filtered with 0.22um ultrafiltration membrane.
  • Chromatographic separation conditions The chromatograph is AKTA pure 150 (purchased from GE), equipped with UV detector and automatic collector. Separation chromatographic column: 1.2kg BioGel P6 (purchased from Bole Company) mixed with deionized water, vacuum degassed, manually packed into a glass column (10cm inner diameter), washed with pure water 10 times the column volume, the column bed is stable , The height is 1.0m. Then use 0.02M NaCl solution as the mobile phase. After equilibrating 10 times the column volume, start loading.
  • the flow rate of the pump is set to 1 mL / min. After 100 mL of the sample solution is pumped to the top of the column by the pump that comes with the chromatograph, switch to the mobile phase and elute at a flow rate of 5 mL / min. After the volume of the stagnant water flowed out, automatic collection was started, and 50 mL was collected per tube.
  • Composition product D Mannuronic acid oligosaccharide having a single degree of polymerization prepared in Example 4 was accurately weighed according to the degree of polymerization from disaccharide to decasaccharide, and the weight of each sugar was as follows: 3.0 g of disaccharide , 3.0g of trisaccharide, 1.5g of tetrasaccharide, 1.5g of pentasaccharide, 0.4g of hexasaccharide, 0.2g of heptasaccharide, 0.2g of octose, 0.1g of nonaperose, 0.1g of decasuose, and mix to obtain 10g of composition product D.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PCT/CN2019/093822 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗糖尿病中的应用 Ceased WO2020001644A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2019296855A AU2019296855A1 (en) 2018-06-29 2019-06-28 Application of composition of mannuronic diacid in treating diabetes
KR1020217001851A KR20210038875A (ko) 2018-06-29 2019-06-28 당뇨병 치료에서의 만누론 이산 조성물의 용도
JP2020572806A JP2021528459A (ja) 2018-06-29 2019-06-28 糖尿病の治療におけるマンヌロン二酸組成物の使用
US17/256,889 US11406652B2 (en) 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of diabetes
EP19824488.1A EP3815690A4 (en) 2018-06-29 2019-06-28 APPLICATION OF A MANNURONIC DIACID COMPOSITION IN THE TREATMENT OF DIABETES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810721304.5 2018-06-29
CN201810721304.5A CN110652526A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗糖尿病中的应用

Publications (1)

Publication Number Publication Date
WO2020001644A1 true WO2020001644A1 (zh) 2020-01-02

Family

ID=68985883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/093822 Ceased WO2020001644A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗糖尿病中的应用

Country Status (7)

Country Link
US (1) US11406652B2 (https=)
EP (1) EP3815690A4 (https=)
JP (1) JP2021528459A (https=)
KR (1) KR20210038875A (https=)
CN (1) CN110652526A (https=)
AU (1) AU2019296855A1 (https=)
WO (1) WO2020001644A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011378A4 (en) * 2019-08-06 2023-08-30 Shanghai Green Valley Pharmaceutical Co., Ltd. USE OF MANNURONIC ACID OLIGOSACCHARIDES OR COMPOSITION COMPRISING THEM IN THE TREATMENT OF DISEASES ASSOCIATED WITH TH1 DOMINANCE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1362860A (zh) * 2000-02-03 2002-08-07 韩国生物高分子株式会社 低分子量聚甘露糖醛酸
CN1933845A (zh) * 2004-03-24 2007-03-21 中国海洋大学 褐藻胶寡糖及其衍生物及其制备方法和用途
US8835403B2 (en) 2004-03-24 2014-09-16 Meiyu Geng Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN106008613A (zh) * 2015-03-27 2016-10-12 全南大学校产学协力团 非还原性末端的不饱和型甘露糖醛酸寡糖及包含其作为有效成分的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889027B (zh) 2007-12-29 2013-05-01 于传兴 低分子量海藻酸及其盐、应用、制法及药物组合物、食品
PL3498722T3 (pl) * 2016-08-15 2021-09-20 Shanghai Green Valley Pharmaceutical Co., Ltd. Sposób przygotowania oligomerycznego dikwasu mannuronowego
JP6977059B2 (ja) * 2016-12-30 2021-12-08 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドShanghai Green Valley Pharmaceutical Co., Ltd. マンヌロン二酸の組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1362860A (zh) * 2000-02-03 2002-08-07 韩国生物高分子株式会社 低分子量聚甘露糖醛酸
CN1933845A (zh) * 2004-03-24 2007-03-21 中国海洋大学 褐藻胶寡糖及其衍生物及其制备方法和用途
CN100508985C (zh) * 2004-03-24 2009-07-08 中国海洋大学 褐藻胶寡糖及其衍生物及其制备方法和用途
US8835403B2 (en) 2004-03-24 2014-09-16 Meiyu Geng Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN106008613A (zh) * 2015-03-27 2016-10-12 全南大学校产学协力团 非还原性末端的不饱和型甘露糖醛酸寡糖及包含其作为有效成分的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3815690A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011378A4 (en) * 2019-08-06 2023-08-30 Shanghai Green Valley Pharmaceutical Co., Ltd. USE OF MANNURONIC ACID OLIGOSACCHARIDES OR COMPOSITION COMPRISING THEM IN THE TREATMENT OF DISEASES ASSOCIATED WITH TH1 DOMINANCE

Also Published As

Publication number Publication date
US20210322449A1 (en) 2021-10-21
KR20210038875A (ko) 2021-04-08
CN110652526A (zh) 2020-01-07
US11406652B2 (en) 2022-08-09
EP3815690A1 (en) 2021-05-05
JP2021528459A (ja) 2021-10-21
AU2019296855A1 (en) 2021-01-28
EP3815690A4 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
US11406659B2 (en) Use of mannuronic diacid composition in treatment of inflammation
WO2020001644A1 (zh) 甘露糖醛二酸的组合物在治疗糖尿病中的应用
WO2020001640A1 (zh) 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
US11406651B2 (en) Use of mannuronic diacid composition in treatment of vascular dementia
WO2020001639A1 (zh) 甘露糖醛二酸的组合物在治疗疼痛中的应用
US20220362271A1 (en) Use of mannuronic acid oligosaccharides or composition comprising same in treatment of th1-dominance related diseases
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation
TW202118493A (zh) 含有褐藻膠寡糖二酸的藥用組合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19824488

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020572806

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217001851

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019296855

Country of ref document: AU

Date of ref document: 20190628

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019824488

Country of ref document: EP

Effective date: 20210129